Visitors to the 59th annual meeting of the American Society of Human Genetics in Honolulu, Hawaii, will have ample opportunity to see the latest state-of-the-art solutions from Oxford Gene Technology (OGT) – ranging from disease research services to cytogenetics research products.
As well as having a strong presence in the exhibitors’ hall, OGT will be showcasing its comprehensive solutions for disease and cytogenetics research at a satellite meeting held in room 325 of the Convention Center at 12 noon on Thursday October 22nd, entitled ‘From disease to cytogenetics research – an integrated CNV analysis platform from Oxford Gene Technology’. In the meeting, Dr Jonathan Sebat, Associate Professor of Human Genetics at Cold Spring Harbor Laboratory, will review some of the challenges in cohort studies, while Dr David Ledbetter, Professor of Human Genetics at Emory University School of Medicine, will elaborate on some of the considerations in taking aCGH to the clinic, including the ISCA Consortium and Public Database.
Dr John Anson, R&D Director at OGT, commented: “We are delighted to welcome two distinguished guest speakers to the podium, who will be discussing developments from disease to cytogenetics research. We will outline how OGT has aligned its portfolio of products and services to support these efforts.”
OGT’s Genefficiency™ genomic services and CytoSure™ cytogenetic aCGH products offer an integrated and standardised solution for array-based disease association studies and cytogenetics research.
Go to http://www.ogt.co.uk/genefficiency for more details and to register for the satellite meeting, or visit OGT at stand 118 to see the very latest technology and services available for CNV analysis.
About Oxford Gene Technology
Founded in 1995 by Professor Ed Southern, OGT has a proven pedigree in microarray technology and services. Our mission is to advance molecular medicine through pioneering discovery and application of molecular technologies. OGT’s key focus areas are: high throughput genomic services and biomarker discovery, cytogenetics, single cell analysis, and licensing.
OGT’s genomic services (Genefficiency™) offer a unique combination of industry leading platforms, expert people and unparalleled sample processing power to rapidly deliver high quality genomic data to customers worldwide.
OGT’s products and services for cytogenetics (CytoSure™) include a range of high resolution oligonucleotide arrays, labelling kits and interpretation software that together provide a complete solution for the detection of chromosomal abnormalities.
Together, Genefficiency™ and CytoSure™ offer a unique, standardised and integrated solution for disease and cytogenetics research.
